MY148880A - N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression - Google Patents

N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Info

Publication number
MY148880A
MY148880A MYPI20091593A MYPI20091593A MY148880A MY 148880 A MY148880 A MY 148880A MY PI20091593 A MYPI20091593 A MY PI20091593A MY PI20091593 A MYPI20091593 A MY PI20091593A MY 148880 A MY148880 A MY 148880A
Authority
MY
Malaysia
Prior art keywords
methyl
ylidene
quinolin
thiazol
benzamide
Prior art date
Application number
MYPI20091593A
Other languages
English (en)
Inventor
Bui Khanh
Dantzman Cathy
Ernst Glen
Hoesch Valerie
Hudzik Thomas
King Megan Murphy
Liu Jie
Yan Jingbo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY148880A publication Critical patent/MY148880A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MYPI20091593A 2006-10-20 2007-10-09 N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression MY148880A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
MY148880A true MY148880A (en) 2013-06-14

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20091593A MY148880A (en) 2006-10-20 2007-10-09 N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Country Status (32)

Country Link
US (2) US7659286B2 (OSRAM)
EP (1) EP2079735B1 (OSRAM)
JP (1) JP4668346B2 (OSRAM)
KR (1) KR20090065534A (OSRAM)
CN (1) CN101528739B (OSRAM)
AR (1) AR063345A1 (OSRAM)
AT (1) ATE543818T1 (OSRAM)
AU (2) AU2007313515B2 (OSRAM)
BR (1) BRPI0717631A2 (OSRAM)
CA (1) CA2667041C (OSRAM)
CL (1) CL2007003009A1 (OSRAM)
CO (1) CO6180450A2 (OSRAM)
CY (1) CY1112718T1 (OSRAM)
DK (1) DK2079735T3 (OSRAM)
ES (1) ES2379519T3 (OSRAM)
HR (1) HRP20120344T1 (OSRAM)
IL (1) IL197876A0 (OSRAM)
MX (1) MX2009003974A (OSRAM)
MY (1) MY148880A (OSRAM)
NO (1) NO20091969L (OSRAM)
NZ (1) NZ577060A (OSRAM)
PE (2) PE20080892A1 (OSRAM)
PL (1) PL2079735T3 (OSRAM)
PT (1) PT2079735E (OSRAM)
RS (1) RS52260B (OSRAM)
RU (1) RU2454414C2 (OSRAM)
SA (1) SA07280549B1 (OSRAM)
SI (1) SI2079735T1 (OSRAM)
TW (1) TW200826939A (OSRAM)
UA (1) UA97648C2 (OSRAM)
UY (1) UY30652A1 (OSRAM)
WO (1) WO2008048171A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
BRPI0912756A2 (pt) * 2008-05-20 2015-10-13 Astrazeneca Ab método para tratar transtorno depressivo maior ansioso em um animal de sangue quente, uso de um composto, composto, e, composição farmacêutica
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2016099393A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
EP3853435B1 (en) 2018-09-21 2024-08-21 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
CN1426411A (zh) * 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
EP1641757A1 (en) * 2003-05-16 2006-04-05 AstraZeneca AB Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) * 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
CY1112718T1 (el) 2016-02-10
TW200826939A (en) 2008-07-01
EP2079735A4 (en) 2010-12-29
EP2079735A1 (en) 2009-07-22
CL2007003009A1 (es) 2008-06-06
ES2379519T3 (es) 2012-04-26
EP2079735B1 (en) 2012-02-01
RU2009111337A (ru) 2010-11-27
HK1131556A1 (en) 2010-01-29
IL197876A0 (en) 2009-12-24
KR20090065534A (ko) 2009-06-22
CA2667041C (en) 2011-09-06
ATE543818T1 (de) 2012-02-15
CA2667041A1 (en) 2008-04-24
RU2454414C2 (ru) 2012-06-27
AR063345A1 (es) 2009-01-21
SA07280549B1 (ar) 2010-09-29
AU2007313515A1 (en) 2008-04-24
PL2079735T3 (pl) 2012-07-31
CN101528739B (zh) 2011-11-30
MX2009003974A (es) 2009-04-27
RS52260B (sr) 2012-10-31
PE20140634A1 (es) 2014-06-19
JP2010506910A (ja) 2010-03-04
PT2079735E (pt) 2012-05-07
UY30652A1 (es) 2008-05-31
US20080182875A1 (en) 2008-07-31
US20100160374A1 (en) 2010-06-24
BRPI0717631A2 (pt) 2013-10-29
WO2008048171A1 (en) 2008-04-24
SI2079735T1 (sl) 2012-05-31
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
NZ577060A (en) 2011-01-28
US7659286B2 (en) 2010-02-09
HRP20120344T1 (hr) 2012-05-31
NO20091969L (no) 2009-05-20
AU2010226996A1 (en) 2010-10-28
JP4668346B2 (ja) 2011-04-13
DK2079735T3 (da) 2012-05-21
PE20080892A1 (es) 2008-09-11
US7977355B2 (en) 2011-07-12
AU2007313515B2 (en) 2010-11-25
CN101528739A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
GEP20115357B (en) Amine derivatives
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
MY148880A (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
NO20091052L (no) Diaryleterderivater og anvendelser derav
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
TW200745122A (en) New compounds I
UA96277C2 (en) Benzimidazole derivatives
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
SE0402284D0 (sv) New heterocyclic amides
GEP20156225B (en) Therapeutic agent for anxiety disorders
DK1778622T3 (da) Para-alkyl-substituerede N-(4-hydroxy-3-methoxy-benzyl)-kanelsyreamider og anvendelse deraf til fremstilling af lægemidler
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
SG143202A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production